A prospective cohort study was performed in patients with angina pectoris who were treated with oral Chinese patent medicine and Western medicine.Collect primary and secondary efficacy indicators such as the incidence of cardiovascular events, using clinical samples to detect genomics, proteomics, metabolomics, intestinal flora and sclerotia.To explore the clinical efficacy of Chinese patent medicine in the treatment of coronary heart disease with angina pectoris, and provide reliable data support for its clinical application.
Study Type
OBSERVATIONAL
Enrollment
12,400
Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
Tianjin University of Traditional Chinese Medicine
Tianjin, Tianjin Municipality, China
Incidence of cardiovascular events
These include acute myocardial infarction (AMI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG).
Time frame: one year
Death from all causes
Time frame: one year
Re-admission due to cardiovascular events
Time frame: one year
Seattle Angina Questionnaire
Time frame: three months
Clinical biochemical test
Time frame: three months
Film degree exam
Time frame: three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.